Molecular and phenotypic data for patients enrolled in the IMmotion150 trial

Dataset ID Technology Samples
EGAD00001004183 Illumina HiSeq 2500 589

Dataset Description

Tumor transcriptome and whole exome sequencing data (matched tumor/normal for somatic mutation calling) along with key phenotypic information are provided for patients enrolled in the phase 2 IMmotion150 trial, assessing efficacy of atezolizumab monotherapy or combination of atezolizumab and bevacizumab versus standard of care (sunitinib) in 1L renal cell carcinoma. This data set accompanies the respective Nature Medicine publication (PMID: 29867230).

Who controls access to this dataset

For each dataset that requires controlled access, there is a corresponding Data Access Committee (DAC) who determine access permissions. Access to actual data files is not managed by the EGA. If you need to request access to this data set, please contact:

Data access committee handling data access requests for biomarker data from the clinical trial IMmotion150.
Contact person: DevSci DAC
Email: devsci-dac-d [at] gene [dot] com
More details: EGAC00001000946


You don't have access to the download section.